TITLE:
A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

CONDITION:
HIV Infections

INTERVENTION:
T-1249

SUMMARY:

      Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen
      to participate in this study) will receive T-1249 at a dose of 200mg daily in combination
      with a background antiretroviral regimen for 96 weeks. Only patients that participated in
      study T1249-102 can participate in study T1249-105.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Completion T1249-102;

          -  Currently failing a T-20 containing regimen

        Exclusion Criteria:

          -  Non-completion of T1249-102.
      
